Related Experiment Video
Updated: Jul 5, 2025
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Induced Pluripotent Stem Cell-Derived Cardiomyocytes Therapy for Ischemic Heart Disease in Animal Model: A
Quan Duy Vo1, Yukihiro Saito2, Kazufumi Nakamura1
1Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
Insights
Induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) therapy shows promise for treating ischemic heart disease (IHD). This meta-analysis found iPSC-CMs improve heart function and reduce fibrosis without increasing mortality or arrhythmias in animal models.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Background:
- Ischemic heart disease (IHD) presents a significant global health challenge with limited therapeutic options.
- Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) represent a promising regenerative medicine approach for cardiac repair.
- The clinical efficacy and safety of iPSC-CM therapy for IHD remain under investigation.
Approach:
- A comprehensive meta-analysis was conducted, searching major databases (PubMed, ScienceDirect, Web of Science, Cochrane Library) up to October 2023.
- The analysis included 51 studies involving 1012 animals to evaluate the impact of iPSC-CM transplantation on cardiac function and safety outcomes in IHD models.
- Statistical methods were employed to assess treatment effects, including improvements in left ventricular ejection fraction (LVEF) and reductions in fibrosis.
Key Points:
- iPSC-CM transplantation significantly improved LVEF by 8.23% (p < 0.001) compared to control groups.
- Cell-based therapy led to a reduction in left ventricle fibrosis area and a trend towards decreased LV volumes (LVESV, LVEDV).
- No significant increase in mortality or arrhythmia risk was observed in the iPSC-CM treatment group.
Conclusions:
- This meta-analysis suggests iPSC-CM therapy is a potentially safe and effective intervention for improving cardiac function in IHD.
- Observed heterogeneity across studies highlights the need for further investigation.
- Large, rigorously designed randomized controlled trials are recommended to confirm the efficacy of iPSC-CM therapy for IHD.
Abstract:
Ischemic heart disease (IHD) poses a significant challenge in cardiovascular health, with current treatments showing limited success. Induced pluripotent derived-cardiomyocyte (iPSC-CM) therapy within regenerative medicine offers potential for IHD patients, although its clinical impacts remain uncertain. This study utilizes meta-analysis to assess iPSC-CM outcomes in terms of efficacy and safety in IHD animal model studies. A meta-analysis encompassing PUBMED, ScienceDirect, Web of Science, and the Cochrane Library databases, from inception until October 2023, investigated iPSC therapy effects on cardiac function and safety outcomes. Among 51 eligible studies involving 1012 animals, despite substantial heterogeneity, the iPSC-CM transplantation improved left ventricular ejection fraction (LVEF) by 8.23% (95% CI, 7.15 to 9.32%; p < 0.001) compared to control groups. Additionally, cell-based treatment reduced the left ventricle fibrosis area and showed a tendency to reduce left ventricular end-systolic volume (LVESV) and end-diastolic volume (LVEDV). No significant differences emerged in mortality and arrhythmia risk between iPSC-CM treatment and control groups. In conclusion, this meta-analysis indicates iPSC-CM therapy's promise as a safe and beneficial intervention for enhancing heart function in IHD. However, due to observed heterogeneity, the efficacy of this treatment must be further explored through large randomized controlled trials based on rigorous research design.
